Literature DB >> 15684305

Drug resistance in tuberculosis.

D A Mitchison1.   

Abstract

A drug-resistant strain of Mycobacterium tuberculosis is defined as one differing from the tight distribution of wild strains that have not come into contact with the drug concerned. Sensitivity tests are performed by the absolute concentration method, the resistance ratio method or the proportion method. The hypothesis underlying the proportion method is that there are appreciable differences in inoculum size so that there should be an association between the proportion on drug-free medium and the proportion on drug-containing medium. This hypothesis was not supported by a study on ethionamide-resistant strains. It indicated that variation in the proportion on drug-free medium was due to clumping of the bacilli in the inoculum rather than to differences in the number of bacilli. Hence, the use of the proportion method introduces errors in susceptibility testing. While the method can produce reliable results, it is more time consuming than a minimal inhibitory concentration determination, and should not be adopted as a standard method.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15684305     DOI: 10.1183/09031936.05.00075704

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  24 in total

Review 1.  The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.

Authors:  Hyungjin Eoh; Patrick J Brennan; Dean C Crick
Journal:  Tuberculosis (Edinb)       Date:  2008-09-14       Impact factor: 3.131

2.  Modification of proportion sensitivity testing method for ethionamide.

Authors:  Rajagopalan Lakshmi; Ranjani Ramachandran; K Devika; G Radhika; A Syam Sundar; Fathima Rahman; N Selvakumar; Vanaja Kumar
Journal:  World J Microbiol Biotechnol       Date:  2013-01-12       Impact factor: 3.312

3.  Solution structure of Rv2377c-founding member of the MbtH-like protein family.

Authors:  Garry W Buchko; Chang-Yub Kim; Thomas C Terwilliger; Peter J Myler
Journal:  Tuberculosis (Edinb)       Date:  2010-07       Impact factor: 3.131

4.  Cisplatin inhibits protein splicing, suggesting inteins as therapeutic targets in mycobacteria.

Authors:  Liyun Zhang; Yuchuan Zheng; Brian Callahan; Marlene Belfort; Yangzhong Liu
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

5.  Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa.

Authors:  T A Thomas; S V Shenoi; S K Heysell; F J Eksteen; V B Sunkari; N R Gandhi; G Friedland; N S Shah
Journal:  Int J Tuberc Lung Dis       Date:  2010-10       Impact factor: 2.373

6.  Inaugural structure from the DUF3349 superfamily of proteins, Mycobacterium tuberculosis Rv0543c.

Authors:  Garry W Buchko; Isabelle Phan; Peter J Myler; Thomas C Terwilliger; Chang-Yub Kim
Journal:  Arch Biochem Biophys       Date:  2010-12-06       Impact factor: 4.013

7.  Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles.

Authors:  Sanaul Mustafa; V Kusum Devi; Roopa S Pai
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

8.  Dilemmas with ethionamide susceptibility testing of Mycobacterium tuberculosis: A microbiologist & physician's nightmare.

Authors:  Mandira Varma-Basil; Rajendra Prasad
Journal:  Indian J Med Res       Date:  2015-11       Impact factor: 2.375

9.  CD8+ DC, but Not CD8(-)DC, isolated from BCG-infected mice reduces pathological reactions induced by mycobacterial challenge infection.

Authors:  Xiaoling Gao; Shuhe Wang; Yijun Fan; Hong Bai; Jie Yang; Xi Yang
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

10.  Rapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual mycobacterium growth indicator tube system.

Authors:  Anandi Martin; Andrea von Groll; Krista Fissette; Juan Carlos Palomino; Francis Varaine; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2008-10-22       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.